Ipsen has announced the start of a Phase II clinical trial to evaluate the safety and efficacy of BN83495, an investigational first-in-class steroid sulfatase (STS) inhibitor to treat advanced endometrial cancer.
The novel treatment, BN83495, will be trialled in an attempt to establish progression-free survival in post-menopausal women with histologically confirmed hormone receptor positive endometrial cancer who are not eligible for treatment with surgery and radiotherapy.
Go deeper with GlobalData
Ipsen executive vice-president Stéphane Thiroloix said that this first-in-class steroid sulfatase inhibitor can potentially significantly improve lives of patients with advanced endometrial cancer.
“With further indications in breast, prostate and ovarian cancers, we believe Ipsen with its focus on hormone dependent cancers will fully leverage the value of BN83495,” he said.
BN83495 is a first-in-class orally available irreversible steroid sulfatase (STS) inhibitor, which prevents the growth of hormone-dependent tumours.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
